BIOTECHNOLOGY EUROPE-ASIA NEWS

Community

Advertising Opportunities

Biotechnology Europe Programs

Resources

Biotechnology Europe Community

BIOTECHNOLOGY EUROPE-JAPAN NEWS



21.06.2010 Designated for Priority Review by Ministry of Health, Labour and Welfare
Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, "Chugai")] announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) designated trastuzumab (genetical recombination), a humanized monoclonal antibody (brand name: Herceptin^® for Intravenous Infusion 60 and 150, hereafter “Herceptin^®”) as a priority review subject on May 18, following an application filed on March 19, 2010 with the MHLW seeking additional approval for the treatment of HER2-positive advanced or recurrent gastric cancer.




































































I back I top I

Biotechnology Europe Your Partner in Bioscience and Business

Central Internet Platform and Service Company For The Life Sciences in Europe